These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25620824)

  • 1. A Multiresolution Hazard Model for Multicenter Survival Studies: Application to Tamoxifen Treatment in Early Stage Breast Cancer.
    Bouman P; Meng XL; Dignam J; Dukić V
    J Am Stat Assoc; 2007 Dec; 102(480):1145-1157. PubMed ID: 25620824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast Cancer.
    Dukić V; Dignam J
    Bayesian Anal; 2007 May; 2(3):591-610. PubMed ID: 21412443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian nonparametric inference on quantile residual life function: Application to breast cancer data.
    Park T; Jeong JH; Lee JW
    Stat Med; 2012 Aug; 31(18):1972-85. PubMed ID: 22437758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Censoring-robust estimation in observational survival studies: Assessing the relative effectiveness of vascular access type on patency among end-stage renal disease patients.
    Nguyen VQ; Gillen DL
    Stat Biosci; 2017 Dec; 9(2):406-430. PubMed ID: 32190128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On adjustment for auxiliary covariates in additive hazard models for the analysis of randomized experiments.
    Vansteelandt S; Martinussen T; Tchetgen ET
    Biometrika; 2014 Mar; 101(1):237-244. PubMed ID: 28669998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiparametric hazard function estimation in meta-analysis for time to event data.
    Wang J
    Res Synth Methods; 2012 Sep; 3(3):240-9. PubMed ID: 26062166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen, hot flashes and recurrence in breast cancer.
    Mortimer JE; Flatt SW; Parker BA; Gold EB; Wasserman L; Natarajan L; Pierce JP;
    Breast Cancer Res Treat; 2008 Apr; 108(3):421-6. PubMed ID: 17541741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible estimation of survival curves conditional on non-linear and time-dependent predictor effects.
    Wynant W; Abrahamowicz M
    Stat Med; 2016 Feb; 35(4):553-65. PubMed ID: 26542758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of time to event outcomes in randomized controlled trials by generalized additive models.
    Argyropoulos C; Unruh ML
    PLoS One; 2015; 10(4):e0123784. PubMed ID: 25906075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiparametric Bayesian analysis of censored linear regression with errors-in-covariates.
    Sinha S; Wang S
    Stat Methods Med Res; 2017 Jun; 26(3):1389-1415. PubMed ID: 25882297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regression-based method for estimating mean treatment cost in the presence of right-censoring.
    Carides GW; Heyse JF; Iglewicz B
    Biostatistics; 2000 Sep; 1(3):299-313. PubMed ID: 12933511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a hazard-based visual predictive check to evaluate parametric hazard models.
    Huh Y; Hutmacher MM
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):57-71. PubMed ID: 26563504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
    Owusu C; Lash TL; Silliman RA
    Breast J; 2007; 13(4):374-82. PubMed ID: 17593042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ["That flesh, pink and perishable": analysis of disease-free survival analysis in breast cancer in Gipuzkoa (Spain) in the presence of competing risks].
    Martínez-Camblor P; Larrañaga N; Sarasqueta C; Mitxelena MJ; Basterretxea M
    Gac Sanit; 2009; 23(6):554-7. PubMed ID: 19748708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of methods for estimating the attributable risk in the context of survival analysis.
    Gassama M; Bénichou J; Dartois L; Thiébaut AC
    BMC Med Res Methodol; 2017 Jan; 17(1):10. PubMed ID: 28114895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in disease free survival between centers: lessons learned from an EORTC breast cancer trial.
    Legrand C; Duchateau L; Sylvester R; Janssen P; van der Hage JA; van de Velde CJ; Therasse P
    Clin Trials; 2006; 3(1):10-8. PubMed ID: 16539086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.